Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, December 2011, Pages: 72

Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Sickle Cell Anemia Therapeutics market. The report identifies the key trends shaping and driving the global Sickle Cell Anemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sickle Cell Anemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Sickle Cell Anemia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sickle Cell Anemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Sickle Cell Anemia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Sickle Cell Anemia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Sickle Cell Anemia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Sickle Cell Anemia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Sickle Cell Anemia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Sickle Cell Anemia Therapeutics market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

1
1

1.1 List of Tables
1.2 List of Figures
2 Sickle Cell Anemia Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.5 Risk Factors
2.6 Diagnosis
2.7 Treatment and Management Pattern
2.8 GlobalData Pipeline Report Guidance
3 Sickle Cell Anemia Therapeutics - Market Characterization
3.1 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Global
3.2 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Global
3.3 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - the US
3.4 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - the US
3.5 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - the UK
3.6 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - the UK
3.7 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - France
3.8 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - France
3.9 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Germany
3.10 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Germany
3.11 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Italy
3.12 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Italy
3.13 Sickle Cell Anemia Therapeutics Market Size (2005-2010) - Spain
3.14 Sickle Cell Anemia Therapeutics Market Forecast (2010-2018) - Spain
3.15 Sickle Cell Anemia Therapeutics Market Size (2005-2010) and Forecast (20102018) - Japan
3.16 Drivers and Barriers for Sickle Cell Anemia
3.16.1 Drivers for the Sickle Cell Anemia Therapeutics Market
3.16.2 Barriers for the Sickle Cell Anemia Therapeutics Market
3.17 Opportunity and Unmet Needs
3.18 Key Takeaway
4 Sickle Cell Anemia Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for the Major Products in Sickle Cell Anemia
4.2.1 Hydroxyurea
4.2.2 Penicillin V
4.3 Key Takeaway
5 Sickle Cell Anemia Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pipeline Analysis by Phase of Development
5.3.1 Sickle Cell Anemia Therapeutics - Phase II / III Pipeline
5.3.2 Sickle Cell Anemia Therapeutics - Phase II Pipeline
5.3.3 Sickle Cell Anemia Therapeutics - Phase I/II Pipeline
5.3.4 Sickle Cell Anemia Therapeutics - Phase I Pipeline
5.3.5 Sickle Cell Anemia Therapeutics - Preclinical Pipeline
5.3.6 Sickle Cell Anemia Therapeutics - Discovery Pipeline
5.4 Sickle Cell Anemia Therapeutics: Pipeline by Mechanism of Action
5.5 Sickle Cell Anemia Therapeutics - Other Promising Mechanisms of Action
5.6 Technology Trends Analytic Framework
5.7 Molecule Profile for Drugs under Phase II Clinical Development
5.7.1 Varespladib sodium (A-001)
5.7.2 Exjade (deferasirox, ICL670)
5.7.3 GMI-1070
5.7.4 HQK-1001
5.8 Key Takeaway
6 Sickle Cell Anemia Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Sponsors Participating in Sickle Cell Anemia Therapeutics Clinical Trials
7 Sickle Cell Anemia Therapeutics - Strategic Assessment
7.1 Future Market Competition Scenario
8 Sickle Cell Anemia Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles for the Promising and Marketed Drugs
8.2.1 Anthera Pharmaceuticals Inc. (Anthera)
8.2.2 Novartis Pharmaceuticals
8.2.3 GlycoMimetics, Inc.
8.2.4 Pfizer
8.2.5 HemaQuest Pharmaceuticals Inc.
8.3 Other Companies in the Sickle Cell Anemia Market, 2011
9 Sickle Cell Anemia Therapeutics - Licensing and Partnership Deals
10 Sickle Cell Anemia Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Prevalence of Sickle Cell Anemia in Major Markets in 2011
Table 2: Sickle Cell Anemia Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 3: Sickle Cell Anemia Therapeutics Market, Global, Market Forecast ($m), 2010-2018
Table 4: Sickle Cell Anemia Therapeutics Market, the US, Revenue($m), 2005-2010
Table 5: Sickle Cell Anemia Therapeutics Market, the US, Market Forecast ($m), 2010-2018
Table 6: Sickle Cell Anemia Therapeutics Market, the UK, Revenue ($m), 2005-2010
Table 7: Sickle Cell Anemia Therapeutics Market, the UK, Market Forecast ($m), 2010-2018
Table 8: Sickle Cell Anemia Therapeutics Market, France, Revenue ($m), 2005-2010
Table 9: Sickle Cell Anemia Therapeutics Market, France, Market Forecast ($m), 2010-2018
Table 10: Sickle Cell Anemia Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 11: Sickle Cell Anemia Therapeutics Market, Germany, Market Forecast ($m),2010-2018
Table 12: Sickle Cell Anemia Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 13: Sickle Cell Anemia Therapeutics Market, Italy, Market Forecast ($m), 2010-2018
Table 14: Sickle Cell Anemia Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 15: Sickle Cell Anemia Therapeutics Market, Spain, Market Forecast ($m), 2010-2018
Table 16: Efficacy results of hydroxyurea for adults with sickle cell anemia
Table 17: Safety results of hydroxyurea for adults with sickle cell anemia
Table 18: Sickle Cell Anemia Therapeutics - Phase II / III Pipeline, 2011
Table 19: Sickle Cell Anemia Therapeutics - Phase II Pipeline, 2011
Table 20: Sickle Cell Anemia Therapeutics - Phase I/II Pipeline, 2011
Table 21: Sickle Cell Anemia Therapeutics - Phase I Pipeline, 2011
Table 22: Sickle Cell Anemia Therapeutics - Preclinical Pipeline, 2011
Table 23: Sickle Cell Anemia Therapeutics - Discovery Pipeline, 2011
Table 24: Sickle Cell Anemia Therapeutics - Other Promising Mechanisms of Action
Table 25: Adverse Effects Due to Deferasirox
Table 26: Sickle Cell Anemia Therapeutics - Clinical Mapping by Region / Country, 2011
Table 27: Sickle Cell Anemia Therapeutics - Clinical Mapping by Phase, 2011
Table 28: Sickle Cell Anemia Therapeutics - Clinical Mapping by Trial Status, 2011
Table 29: Sickle Cell Anemia Therapeutics - Clinical Mapping by Overall Sponsors, 2011
Table 30: Sickle Cell Anemia Therapeutics - Clinical Mapping by Prominent Sponsors, 2011
Table 31: Sickle Cell Anemia Therapeutics - Clinical Mapping by Top Sponsors, 2011
Table 32: Anthera Pharmaceuticals - Pipeline Products, 2011
Table 33: Anthera Pharmaceuticals - Sickle Cell Anemia Pipeline Product, 2011
Table 34: Novartis Pharmaceuticals - Pipeline Products, 2011
Table 35: Novartis Pharmaceuticals - Sickle Cell Anemia Pipeline Product, 2011
Table 36: Glyco Mimetics Inc.- Pipeline Products, 2011
Table 37: Glyco Mimetics Inc.- Sickle Cell Anemia Pipeline Product, 2011
Table 38: HemaQuest Pharmaceuticals Inc. - Pipeline Product, 2011
Table 39: HemaQuest Pharmaceuticals Inc. - Sickle Cell Anemia Pipeline Product, 2011
Table 40: Sickle Cell Anemia Therapeutics - Future Players, 2011
Table 41: Sickle Cell Anemia Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Pictorial Representation of Normal and Abnormal Red Blood Cells
Figure 2: Inheritance Pattern of Sickle Cell Trait
Figure 3: Types of Sickle Cell Disease
Figure 4: Symptoms of Sickle Cell Anemia
Figure 5: Complications of Sickle Cell Anemia
Figure 6: Sickle Cell Anemia Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 7: Sickle Cell Anemia Therapeutics , Market Share (%), 2010
Figure 8: Sickle Cell Anemia Therapeutics Market, Global, Market Forecast ($m), 2010-2018
Figure 9:Sickle Cell Anemia Therapeutics, Market Share (%), 2018
Figure 10: Sickle Cell Anemia Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 11: Sickle Cell Anemia Therapeutics Market, the US, Market Forecast ($m), 2010-2018
Figure 12: Sickle Cell Anemia Therapeutics Market, the UK, Revenue ($m), 2005-2010
Figure 13: Sickle Cell Anemia Therapeutics Market, the UK, Market Forecast ($m), 2010-2018
Figure 14: Sickle Cell Anemia Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 15: Sickle Cell Anemia Therapeutics Market, France, Market Forecast ($m), 2010-2018
Figure 16: Sickle Cell Anemia Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 17: Sickle Cell Anemia Therapeutics Market, Germany, Market Forecast ($m), 2010-2018
Figure 18: Sickle Cell Anemia Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 19: Sickle Cell Anemia Therapeutics Market, Italy, Market Forecast ($m), 2010-2018
Figure 20: Sickle Cell Anemia Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 21: Sickle Cell Anemia Therapeutics Market, Spain, Market Forecast ($m), 2010-2018
Figure 22: Sickle Cell Anemia Therapeutics Market, Quotes from Japanese Hematologists
Figure 23: Sickle Cell Anemia Therapeutics - Drivers and Barriers, 2011
Figure 24: Opportunity and Unmet Need for adults in Sickle Cell Anemia Therapeutics Market, 2011
Figure 25: Strategic Competitor Assessment of Sickle Cell Anemia Therapeutics Market, 2011
Figure 26: Sickle Cell Anemia Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 27: Sickle Cell Anemia Therapeutics - Clinical Pipeline by Mechanism of Action, 2011
Figure 28: Technology Trends Analytic Framework of the Sickle Cell Anemia Therapeutics Pipeline, 2011
Figure 29: Technology Trends Analytic Framework of the Sickle Cell Anemia Therapeutics Pipeline - Description, 2011
Figure 30: Sickle Cell Anemia Therapeutics - Clinical Mapping by Region / Country, 2011
Figure 31: Sickle Cell Anemia Therapeutics - Clinical Mapping by Phase, 2011
Figure 32: Sickle Cell Anemia Therapeutics - Clinical Mapping by Trial Status, 2011
Figure 33: Sickle Cell Anemia Therapeutics - Clinical Mapping by Overall Sponsors, 2011
Figure 34: Sickle Cell Anemia Therapeutics - Clinical Mapping by Prominent Sponsors, 2011
Figure 35: Sickle Cell Anemia Therapeutics - Clinical Mapping by Top Sponsors, 2011
Figure 36: Sickle Cell Anemia Therapeutics - Implications for Future Market Competition, 2011
Figure 37: Sickle Cell Anemia Therapeutics - Clinical Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global sickle cell anemia market. The report identifies the key trends shaping and driving the global sickle cell anemia market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global sickle cell anemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Sickle Cell Anemia Therapeutics Market is Forecast to Show Slow Growth Until 2018

GlobalData valued the global (to include the US, the UK, France, Germany, Italy, Spain and Japan) Sickle Cell Anemia therapeutics market at $33m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 18.9% to reach $130m in 2018. There are no approved branded drugs in the sickle cell anemia market. The Phase II pipeline has two potential novel molecules GMI-1070 (orphan drug and fast track status by US Food and Drug Administration (FDA)) and HQK-1001 (orphan drug in the US and Europe).These drugs are expected to be launched in the forecast period. GMI-1070 is expected to replace the use of hydroxyurea in adolescents and adults in the near future. However, the market is expected to have slow growth until 2018.

Sickle Cell Anemia Therapeutics Market, Global, Revenue and Forecast ($m), 2005–2018

Source: GlobalData, Centers for Disease Control and Prevention, Human Genome Project Information, Sickle cell Association of America, Sickle cell society, UK, American Society of haematology, International Society of Hematology, Association of sickle cell disease Orleans, France, New England Journal of Medicine, National Heart, Lung and Blood Institute, World Health Organization, GlobalData Epidemiology-based Market Forecasting Model, Primary Research Interviews, Key Opinion Leader (KOL) Interviews

Current Competition in Sickle Cell Anemia Therapeutics Market is Weak

Current competition in the sickle cell anemia therapeutics market is weak. The current market is weak due lack of approved drugs in the market. GlobalData anticipates that the only approved drug hydroxyurea (for treatment of adult patients) despite being generic would remain the leader in the sickle cell anemia treatment drugs market alongwith Penicillin V (off-label drug) used for the treatment of pediatric patients. Novel drugs in Phase II of the pipeline, if launched, could depict improved efficacy, safety and patient compliance than the currently available options.

Anthera Pharmaceuticals Inc. (Anthera)
Novartis Pharmaceuticals
GlycoMimetics, Inc.
Pfizer
HemaQuest Pharmaceuticals Inc.

Customers who bought this item also bought

• Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
• Sickle Cell Disease Global Clinical Trials Review, H2, 2012
• Global Sickle Cell Anaemia Drug Pipeline Capsule - 2011
• Global Hematologic Disorders Drug Pipeline Capsule – 2012
• Global Sickle Cell Anaemia Drug Pipeline Capsule - 2012
• Global Sickle Cell Anaemia Drug Pipeline Capsule - 2012 Update
• Anemia Drugs - Global Strategic Business Report
• Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders
• Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018